Ellens, H, Deng, S, Coleman, J, Bentz, J, Taub, ME, Ragueneau-Majlessi, I, Chung, SP, Heredi-Szabo, K, Neuhoff, S, Palm, J, Balimane, P, Zhang, L, Jamei, M, Hanna, I, O'Connor, M, Bednarczyk, D, Forsgard, M, Chu, X, Funk, C, Guo, A, Hillgren, KM, Li, L, Pak, AY, Perloff, ES, Rajaraman, G, Salphati, L, Taur, JS, Weitz, D, Wortelboer, HM, Xia, CQ, Xiao, G, Yamagata, T and Lee, CA (2013) Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions. DRUG METABOLISM AND DISPOSITION. pp. 1367-1374.

Item Type:	Article
Additional Information:	pubid: 24 nvp_institute: NIBR contributor_address: GlaxoSmithKline, Stat Sci, King Of Prussia, PA USA, GlaxoSmithKline, Drug Metab & Pharmacokinet, King Of Prussia, PA USA ; Pfizer Worldwide Res & Dev La Jolla Labs, Clin Res, San Diego, CA USA ; GlaxoSmithKline, Stat Sci, King Of Prussia, PA USA ; Drexel Univ, Dept Biol, Philadelphia, PA 19104 USA ; Boehringer Ingelheim Pharmaceut Inc, Drug Metab & Pharmacokinet, Ridgefield, CT USA ; Univ Washington, Dept Pharmaceut, Drug Interact Database Program, Seattle, WA 98195 USA ; SOLVO Biotechnol, Budapest, Hungary ; SimCyp, Sheffield, S Yorkshire, England ; AstraZeneca Res & Dev, CVGI iMed DMPK, Innovat Med, Molndal, Sweden ; Bristol Myers Squibb, Pharmaceut Candidate Optimizat, Princeton, NJ USA ; US FDA, Off Clin Pharmacol, Off Translat Sci, Ctr Drug Evaluat & Res, Silver Spring, MD USA ; Novartis Inst BioMed Res, Drug Metab & Pharmacokinet, E Hanover, NJ USA ; Optivia, Biotechnol, Menlo Pk, CA USA ; AstraZeneca Res & Dev, Global Drug Metab & Pharmacokinet, Molndal, Sweden ; Merck Co, Dept Pharmacokinet Pharmacodynam & Drug Metab, Rahway, NJ USA ; Hoffmann La Roche AG, Nonclin Drug Safety, Basel, Switzerland ; Lilly Res Labs, Investigat Drug Disposit, Indianapolis, IN USA ; Absorpt Syst LP, Exton, PA USA ; BD Gentest Contract Res Serv, BD Bioscie Discovery Labware, Woburn, MA USA ; CellzDirect Life Technol Ltd, Austin, TX USA ; Genentech Inc, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA ; Eisai Inc, Andover, MA USA ; Sanofi Aventis, DSAR Drug Disposit FF, Res & Dev, Frankfurt, Germany ; TNO, NL-3700 AJ Zeist, Netherlands ; Millennium Pharmaceut Inc, Cambridge, MA USA ; Biogen Idec Inc, Drug Metab & Pharmacokinet, Cambridge, MA USA ; Merck Serono, Inst Drug Metab & Pharmacokinet, Grafing, Germany ; Pfizer Worldwide Res & Dev La Jolla Labs, Pharmacokinet Dynam & Metab, San Diego, CA USA ; GlaxoSmithKline, Stat Sci, King Of Prussia, PA USA; GlaxoSmithKline, Drug Metab & Pharmacokinet, King Of Prussia, PA USA; Ellens, H; GlaxoSmithKline, Drug Metab & Pharmacokinet, King Of Prussia, PA USA
Date Deposited:	13 Oct 2015 13:13
Last Modified:	13 Oct 2015 13:13
URI:	https://oak.novartis.com/id/eprint/21876